Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

NCT00463788 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

181

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasm

Interventions

DRUG: cetuximab, cisplatin
DRUG: cisplatin

Sponsor

Merck KGaA, Darmstadt, Germany